The microtubule-targeting antineoplastic agent, paclitaxel, is highly efficacious against a wide spectrum of human cancers. However, dose-limiting toxicity and development of drug resistance limit its clinical application. Development of novel strategies that overcome chemoresistance and sensitize cancer cells to paclitaxel can enhance the therapeutic effect of this drug. We have previously shown that curcumin, a natural polyphenol, enhances paclitaxelinduced cytotoxicity in vitro through downregulation of nuclear factor (NF)-jB and Akt pathways. This study was undertaken to determine whether this synergism exists in vivo and to elucidate the underlying molecular mechanisms. Mouse cervical multistage squamous cell carcinoma model using 3-methylcholanthrene (3-MC) and a xenograft model of human cervical cancer in nonobese diabetic severe combined immunodeficient (NOD-SCID) mice using HeLa cells were used to evaluate the synergism. We observed that the combined treatment of curcumin and paclitaxel induced a synergestic reduction in the tumor incidence as well as tumor volume of animals compared with the individual treatments of paclitaxel or curcumin, although curcumin alone could not induce any significant effect at the concentration used. The results suggest that a suboptimal concentration of curcumin augments the antitumor action of paclitaxel by downregulating the activation and downstream signaling of antiapoptotic factors and survival signals such as NF-jB, Akt and mitogen-activated protein kinases that have significant roles in proliferation, survival, angiogenesis and metastasis. This study revealed for the first time that 3-MC-induced tumorigenesis in mice is associated with a strong constitutive activation of NF-jB activity. Furthermore, we also observed that pre-exposure of carcinoma cells isolated from 3-MC-induced tumors to curcumin potentiates paclitaxel-induced apoptosis. Overall, the findings of this preclinical study provide a strong rationale for the validation of this combination through clinical trials. As curcumin could effectively downregulate all these survival signals induced by paclitaxel, we suggest it as a potent chemosensitizer to improve the therapeutic index of paclitaxel.
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Introduction
Paclitaxel, isolated from Taxus brevifolia, is one of the commonly prescribed chemotherapeutic agents against a wide spectrum of epithelial cancers (Blagosklonny and Fojo, 1999) . In addition to its classical microtubulestabilizing activity, several studies have demonstrated that it induce apoptosis in a number of solid tumor cells (Chang et al., 1996; Lanni et al., 1997; Saunders et al., 1997; Bava et al., 2005) . However, the clinical efficacy and usefulness of paclitaxel-based treatment regimens is still limited because of dose-limiting toxicity and induction of drug resistance (Marupudi et al., 2007) . Chemoresistance toward paclitaxel is speculated to be multifactorial, involving the activation of nuclear factor (NF)-kB, upregulation of cytoprotective pathways such as Akt and mitogen-activated protein kinase (MAPK), elevated expression levels of multidrug resistance-1 (MDR-1) gene, alterations in b-tubulin isotypes (Giannakakou et al., 1997; Yusuf et al., 2003; Kim et al., 2007; Ahn et al., 2008) , alterations in the intrinsic apoptotic pathway (Kutuk and Letai, 2008) and so on.
Curcumin is known as an ideal chemopreventive because of its diverse effects on multiple signaling pathways (Kunnumakkara et al., 2008) . The ability of curcumin to downregulate the activation of NF-kB and the expression of its target genes induced by diverse agents and anticancer drugs has been well documented (Singh and Aggarwal, 1995; Aggarwal et al., 2007) . Accumulating evidence also suggests that this compound possesses potent antiproliferative, antiangiogenic, antimetastatic and proapoptotic properties in vitro as well as in vivo (Anto et al., 2002; Li et al., 2005; Aggarwal et al., 2006; Reuter et al., 2008) .
Although the individual anticancer effects of paclitaxel and curcumin have been evaluated comprehensively, the combinatorial anticancer potential of these compounds has not been extensively studied. We have previously shown that curcumin could significantly enhance paclitaxel-induced apoptosis in HeLa cells by inhibiting the activation of NF-kB and Akt (Bava et al., 2005) . The augmentation of therapeutic efficacy of paclitaxel by curcumin in ovarian cancer cells by co-administering nanoemulsion formulations of these compounds is also recently reported (Ganta and Amiji, 2009 ). However, apart from a xenograft study using human breast cancer cells (Aggarwal et al., 2005) , the combination of paclitaxel and curcumin has not been tested in vivo.
Based on our earlier in vitro observations on the synergistic anticancer activity of curcumin and paclitaxel (Bava et al., 2005) , we carried out two preclinical studies, one a carcinogen-induced multistage tumor model that better reflects the architectural and cellular complexity of patient-derived tumor specimens and the other a human cervical cancer xenograft model in nonobese diabetic severe combined immunodeficient (NOD-SCID) mice. We have identified for the first time that activation of NF-kB is associated with 3-methylcholanthrene (3-MC)-induced tumorigenesis in Swiss albino mice and the suppression of NF-kB activation and other survival signals by curcumin leads to the augmentation of paclitaxel-induced apoptosis, thereby enhancing the therapeutic outcome of paclitaxel in vivo.
Results
Curcumin potentiates the antitumor effects of paclitaxel in 3-MC-induced cervical tumors in mice Following tumor induction with 3-MC, palpable tumors began to appear within 20-25 days. Tumors developed in the group I and curcumin-alone-treated group III animals continued to grow during the span of the experiment and reached the maximum volume up to 5500 mm 3 , whereas 460% of the tumors in the paclitaxel-alone group and 485% of the combinationtreated tumors did not grow beyond a volume of B3200 mm 3 . The final tumor incidence percentage ( Figure 1B ) and the mean tumor volume ( Figure 1C ) among different groups were determined after killing the animals on day 120. In group I, 66% of the animals treated with 3-MC (positive control) developed tumors with a mean tumor volume of 1613.24±173.42 mm 3 . In groups II and III, where the animals received either paclitaxel or curcumin, respectively, the tumor incidence percentages were 44 and 60%, and the mean tumor volume among these groups was 965.07 ± 115.96 and 1293.49 ± 139.89 mm 3 , respectively. Mice of group IV, which received both paclitaxel and curcumin, showed a tumor incidence of only 24%, and the mean tumor volume was reduced to 655.54 ± 100.20 mm 3 , indicating a clear synergism for paclitaxel and curcumin against 3-MC-induced cervical carcinogenesis. None of the animals from groups V and VI (negative controls) showed any signs of tumor development during the span of the study, and the mean volume of the excised cervix samples from these groups was 245.10 ± 27.89 and 190.90±24.54 mm 3 , respectively. Moreover, 3-MC treatment or administration of paclitaxel and/or curcumin had no adverse effects on the tumor-bearing animals or normal controls (group VI) as assessed by body weight observation and liver function tests (data not shown). Microscopic analysis of the formalin-fixed paraffin-embedded tissue sections showed different grades of squamous cell carcinoma, and this observation was verified by a histopathologist. Representative photomicrographs of hematoxylin and eosin-stained tissue sections showing 3-MC-induced multistage squamous cell carcinogenesis are given in Figure 1D .
Curcumin inhibits constitutively active and paclitaxelinduced NF-kB in 3-MC-induced cervical tumors and downregulates the transcription of NF-kB target genes As most of the carcinogens and infectious agents linked with cancer have been shown to activate the NF-kB pathway, we investigated whether NF-kB is associated with 3-MC-induced cervical tumorigenesis. Although constitutive activation of NF-kB and higher levels of nuclear DNA-binding activity was observed in 3-MCinduced cervical tumors and 3-MC þ paclitaxel-treated animals, administration of curcumin abolished the constitutively activated as well as paclitaxel-induced NF-kB. Incubation of DNA-protein complexes with p65 antibody resulted in the supershift of active band ( Figure 2A ). To further confirm the activation of NF-kB by 3-MC and paclitaxel, we examined the NF-kB DNAbinding activity in 10 tissue samples each from the 6 experimental groups. But in few (o10%) of the tumorbearing mice, curcumin was unable to inhibit the NF-kB activity, probably because of the need for a higher dose or any genetic variability among animals ( Figure 2B ). Immunohistochemical analysis of tissue samples harvested from 3-MC alone and 3-MC þ paclitaxel-treated animals revealed increased expression and prominent nuclear localization of the p65 subunit of NF-kB in comparison with normal cervical epithelium ( Figure 2C ). Consistent with the results obtained from electrophoretic mobility shift assay (EMSA), curcumin could downregulate the expression and nuclear localization of p65 in tissue samples derived from curcumin and curcumin þ paclitaxel-treated mice. Having established the association between NF-kB activation and 3-MCinduced tumor progression, we analyzed the functional status of NF-kB activation by assessing the mRNA expression levels of NF-kB target genes such as Cox-2, cyclin D1, ICAM-1, VEGF, MMP-2 and MMP-9 by real-time quantitative reverse transcriptase-PCR. Tissue samples from groups I and II showed high mRNA expression levels of these genes, whereas low levels were detected in the tumor samples collected from animals treated with curcumin either alone or in combination with paclitaxel ( Figure 2D ). One animal from the curcumin group and one animal from the paclitaxel þ curcumin group developed very big tumors compared with other members of the respective groups, although exactly the same mode of tumor initiation and drug treatment was provided to them as to the other members of the respective groups. Hence, these 'highly aggressive' tumors were separately analyzed for the status of survival signals. Samples indicated with '*' represents these tumors that show no sensitivity to either individual or combination therapy.
Curcumin represses NF-kB-dependent gene products, potentiates the antiproliferative effect of paclitaxel and enhances paclitaxel-induced caspase activation Western blot analyses revealed that paclitaxel either further induced or did not downregulate 3-MC-induced activity of various NF-kB-regulated gene products Cox-2, cyclin D1, MMP-2, MMP-9 and VEGF that are directly involved in tumor cell proliferation, angiogenesis and metastasis ( Figure 3A ). Immunohistochemical analysis for the cell proliferation marker, proliferating cell nuclear antigen, in the tissue samples revealed that curcumin significantly enhanced paclitaxel-induced inhibition of proliferation as evidenced by reduced proliferating cell nuclear antigen immunoreactivity compared with the positive control group ( Figure 3B ). Diverse antiapoptotic proteins such as Bcl-2, c-IAP1, survivin and XIAP, which are reported to be transactivated by NF-kB, were also found to be upregulated in most of the tumor samples collected from 3-MC-alone and 3-MC þ paclitaxel groups ( Figure 3C ). The expression levels of these molecules were significantly downregulated by curcumin. We also observed the cleavage and activation of procaspases 8, 9, 3 and 7 in paclitaxel-treated cervical tumors of mice, which was significantly upregulated when curcumin was co-administered ( Figure 3D ). Curcumin-mediated augmentation of antitumor effects of paclitaxel in 3-MC-induced cervical tumors involves the downregulation of Akt, MAPK and activator protein-1 (AP-1) pathways Immunoblotting with a phospho-specific antibody against Akt at Ser473 points toward the hyperactivation of Akt by phosphorylation in 3-MC-induced tumors compared with normal controls. More interestingly, the animals that were administered curcumin, either alone or in combination with paclitaxel, showed relatively low expression levels of phospho-Akt in comparison with the carcinogen-alone or paclitaxel-treated groups. But, overexpression and hyperactivation of Akt was observed in well-developed tumors from curcumin-treated animals ( Figure 4b ). It was very interesting to note that although we observed an induction of total Akt in one of the vehicle control samples, no induction of hyperphosphorylated Akt was noted in this sample too, showing that the downregulation of hyperphosphorylated Akt in 3-MC-induced tumors by curcumin is the prominent determining factor of synergism rather than total Akt levels. We also found hyperphosphorylation at Ser136 of Bad, a well-known direct target of phosphorylation and inactivation by Akt, indicating a possible antiapoptotic effect of activated Akt. The expression and activation status of the three important MAP kinases-extracellular signal-regulated protein kinase (ERK), c-Jun-NH2 kinase (JNK), and p38-were analyzed by western blotting and extensively high phosphorylation of ERK-1/2 and JNK was observed in most of the 3-MC-induced tumor samples when compared with normal controls. Paclitaxel treatment alone did not alter the phosphorylation levels of ERK-1/2 and JNK in the tumor tissues, whereas administration of curcumin, alone or in combination with paclitaxel, inhibited the phosphorylation of these molecules significantly. On the other hand, the phosphorylation and expression status of p38 was not found to significantly vary among the experimental groups, indicating a lesser role of p38 in mediating the carcinogenic action of 3-MC as well as in the chemotherapeutic action of paclitaxel and curcumin ( Figure 4c ), although we observed a downregulation of paclitaxel-induced activation of p38 by curcumin in the human cervical cancer cell line, HeLa (Bava et al., 2010) . The expression of phospho-c-jun, a proto-oncogene that is the direct target of both JNK and ERK-1/2 and the central component of all AP-1 complexes (Karin, 1995) , was found elevated in those samples with high levels of phospho-JNK and phospho-ERK1/2 (Figure 4c) . Moreover, the significantly higher levels of nuclear DNAbinding activity of AP-1 detected in 3-MC-induced tumor samples was suppressed by curcumin alone or in combination with paclitaxel.
Curcumin enhances the cytotoxic effect of paclitaxel in mouse cervical carcinoma cells in vitro by downregulating the activation of NF-kB To further delineate the molecular mechanisms behind the synergism, we carried out in vitro experiments using primary cells isolated from the 3-MC-induced cervical tumors, the epithelial origin of which were confirmed by cytokeratin immunostaining (data not shown). Among the different combinations tried, the combination of 10 mM curcumin and 10 nM paclitaxel showed maximum synergistic cytotoxic effect and reduced the relative cell viability from 76 to 56%. Thus, a relatively subcytotoxic dose of curcumin elevated the cytotoxic potential of paclitaxel by 20%. Furthermore, no apparent cytotoxicity was induced by any of these compounds, individually or in combination on normal mouse cervical cells (Figure 5a ). Although cell cycle analysis did not show any significant effect of curcumin on cell death within 24 h, we noticed a blockage of cell cycle progression at S and G2/M phases to a minor level by 25 mM curcumin. Paclitaxel, at 10 and 25 nM concentrations, induced cell cycle arrest at the G2/M stage and also induced the hypodiploid/fragmented DNA stage (sub-G0 peak in the histogram) within 24 h. Interestingly, pretreatment with 10 mM curcumin significantly increased paclitaxelinduced cell death from 21.2 to 33.5% (Figure 5c ). A constitutive activation and high DNA-binding activity of NF-kB was observed in the carcinoma cells. Although treatment with curcumin for 4 h downregulated the constitutive NF-kB activation in a dose-dependent manner, paclitaxel treatment further increased the nuclear levels of NF-kB. Remarkably, 10 nM paclitaxel could not promote NF-kB activation when the cells were pretreated with curcumin ( Figure 5c ). Immunocytochemical analysis using p65 and p50 antibodies confirmed the EMSA results, wherein the constitutive nuclear localization of NF-kB subunits in carcinoma cells was inhibited by curcumin. Treatment with paclitaxel for 30 min resulted in the nuclear translocation of NF-kB subunits, whereas pretreatment with 10 mM curcumin for 4 h before paclitaxel treatment localized the NF-kB subunits in the cytoplasm (Figure 5d ).
Curcumin enhances paclitaxel-induced membrane flip-flop, DNA fragmentation and poly(ADP-ribose) polymerase cleavage in mouse carcinoma cells Flow cytometric analysis of curcumin-and/or paclitaxeltreated cells stained with fluorescein isothiocyanateconjugated Annexin V and propidium iodide revealed that the relative Annexin-staining percentage was significantly high in the cells treated with the combination (Figure 6a ). Curcumin (10 mM) enhanced paclitaxel (10 nM)-induced internucleosomal fragmentation of nuclear DNA, which is an important hallmark of apoptotic cell death (Figure 6b ). The same combination also induced an extensive cleavage of the DNA repair enzyme poly(ADP-ribose) polymerase, which is a typical characteristic of apoptotic cells (Figure 6c ).
The combined treatment of paclitaxel and curcumin decreases the tumor volume, downregulates NF-kB and enhances apoptosis in human cervical cancer xenografts compared with individual treatments in NOD-SCID mice The mean tumor volume at the time of necropsy in the untreated control group was 2.66 cm 3 , and administration of curcumin alone did not show any significant effect on the xenograft tumor growth and the mean tumor volume was 2.47 cm 3 . Paclitaxel treatment alone suppressed the growth of HeLa xenograft tumors and reduced the final mean tumor volume to 1.83 cm 3 , whereas curcumin considerably enhanced the antitumor activity of paclitaxel, and the remarkable synergistic antitumor efficacy of these compounds resulted in a mean tumor volume of 1.32 cm 3 at the time of necropsy (Figures 7a and b) . Nuclear extracts prepared using tumor samples were used for EMSA, and higher NF-kB activation levels were observed in the untreated tumors, whereas paclitaxel treatment resulted in a further upregulation of NF-kB activation levels. On the contrary, curcumin treatment, either alone or in combination with paclitaxel, significantly downregulated the nuclear DNA-binding activity of NF-kB in vivo (Figure 7c ). These results confirmed that suppression of paclitaxel-induced NF-kB activation by curcumin is an important molecular mechanism by which this compound sensitizes HeLa xenograft tumors in NOD-SCID mice to paclitaxel therapy. The in vivo apoptotic effects of curcumin and/or paclitaxel in ectopically implanted human cervical cancer xenografts in NOD-SCID mice were assessed by terminal deoxy-nucleotidyl transferasemediated nick end labeling (TUNEL) staining. As shown in Figure 7d , tumor sections from control-and curcumin-alone-treated groups did not show any considerable positivity for apoptotic cells, whereas paclitaxel-treated samples showed substantial amount of TUNEL staining. More interestingly, in tumor samples collected from animals treated with both the agents, curcumin could significantly enhance the apoptotic effects of paclitaxel in comparison with the individual treatment.
Discussion
The major drawbacks associated with paclitaxel therapy are the dose-limiting toxicity and development of drug resistance, which warrants innovative strategies that can ensure the optimal use of this frontline chemotherapeutic agent in clinic. Almost 100% of human cervical carcinoma is initiated by human papillomavirus (HPV). As mouse is not a host for HPV, there is no efficient mouse model available to study the initiation and progression of cervical carcinoma by HPV, except the model by Brake and Lambert (2005) that uses HPV16 transgenic mice along with exogenous supply of estrogen. Hence, to evaluate the molecular changes involved in the initiation and progression of cervical carcinoma, we used chemical-induced cervical carcinogenesis model. The cellular changes we observed in the cervical epithelium following 3-MC treatment closely resemble the progressive stages of human squamous cell carcinoma that constitute 80% of human cervical cancer. Nair et al (2003) have reported that there is an increased nuclear localization and DNA-binding activity of NF-kB as the grade of human cervical cancer progresses, which was also reflected in our 3-MC model, making it a suitable model for evaluating the synergistic effect of paclitaxel and curcumin in vivo. To validate the results obtained in the 3-MC model, we used the xenograft model using human cancer cell line HeLa, which has HPV oncogenes integrated within. The confirmation of the synergistic effect of paclitaxel and curcumin in this clinically relevant model signifies the therapeutic potential of the synergism.
In this study, using a chemical carcinogen-induced preclinical tumor model and the xenograft cervical cancer model, we have shown how a suboptimal dose of the nontoxic dietary phytochemical curcumin circumvents the mechanisms of paclitaxel resistance and sensitizes tumor cells to paclitaxel treatment. The inconsistent findings on curcumin bioavailability in preclinical and clinical studies continue to be a major concern (Anand et al., 2007) and recent evidences suggest that liposomal encapsulation enhances its bioavailability and makes this compound amenable to systemic dosing Narayanan et al., 2009) . In this study we encapsulated curcumin into unilamellar liposomes and injected intraperitoneally in order to improve its bioavailability and to eliminate dosing variability.
The initial gross observations on the percentage of tumor-bearing animals as well as mean tumor volume among different experimental groups provided an early hint about the synergistic anticancer activity of paclitaxel and curcumin against 3-MC-induced carcinogenesis. More interestingly, paclitaxel-curcumin combination therapy afforded significantly better tumor response than standard single-drug treatment. Consistent with previous reports (Chhabra et al., 1995) , histopathological analysis of 3-MC-induced cervical tumors derived from our study revealed different stages of squamous cell carcinoma, and such progressive multistage carcinogenesis models better reflect the molecular and cellular complexity of human epithelial tumors.
Consistent with the role of NF-kB in oncogenesis and survival, cumulative experimental and epidemiological evidence demonstrates the prevalence of aberrant constitutive activation of NF-kB in human tumors of diverse tissue origin and in various cancer cell lines (Nakshatri et al., 1997; Sumitomo et al., 1999; Tai et al., 2000; Sasaki et al., 2001; Karin et al., 2002; Aggarwal, 2004; Tang et al., 2006; Zhang et al., 2006; Logan et al., 2007; Sur et al., 2008; Prasad et al., 2010) . The nuclear expression of NF-kB might be considered as an indicator of malignant transformation and, interestingly, it is well demonstrated that NF-kB is constitutively activated during human cervical cancer progression (Nair et al., 2003) . Reports also indicate that inhibition of NF-kB ameliorates the pathogenesis and overcomes therapeutic resistance (Ahn et al., 2007) . Moreover, paclitaxel induces NF-kB activation in several cell types, and adjuvants that inhibit NF-kB function can enhance its therapeutic efficiency (Bava et al., 2005; Logan et al., 2007; Inoue et al., 2008) . To our knowledge, this is the first report to reveal the strong association of constitutive NF-kB activity with 3-MCinduced tumorigenesis in mice, and we found that curcumin suppresses the nuclear translocation and DNA-binding activity of NF-kB very effectively in the tumor tissues when given alone or in combination with paclitaxel. The results of the xenograft experiments using HeLa cells also corroborate the central findings of the 3-MC-induced multistage carcinogenesis study, and together they suggest that the administration of curcumin along with paclitaxel can potentially enhance the therapeutic outcome of paclitaxel in vivo.
The transcriptional activation and overexpression of NF-kB target gene products such as the stress response protein Cox-2, cell cycle regulatory protein cyclin D1, cell adhesion molecule ICAM-1, proteolytic enzymes such as matrix metalloproteinases-2 and 9 and the angiogenic factor VEGF in human cancers is well documented (Aggarwal et al., 2005) . Our data substantiate the ability of curcumin to circumvent the detrimental effects of oncogenic NF-kB, such as induction of proliferation, cell invasion, metastasis and angiogenesis. The expression patterns of several NF-kBdependent antiapoptotic genes such as Bcl-2, Survivin, XIAP, c-IAP and so on in the tissue samples showed excellent correlation with the NF-kB activity, and consequently cells with elevated NF-kB activity will be more resistant to paclitaxel-induced cell death. As these proteins have central roles in suppression of apoptosis, their inhibition by curcumin can enhance the apoptotic activity of paclitaxel when given together. This notion is confirmed by increased caspase activation observed in the tumor samples treated with the combinatorial regimen.
In many human malignancies, overexpression of the MDR-1 gene product P-glycoprotein is a major obstacle to effective chemotherapy and it functions as an energydependent efflux pump for which paclitaxel is a substrate (Bradley and Ling, 1994) . In addition, MDR-1 gene expression is regulated by NF-kB in different cell types (Zhou and Kuo, 1997; Thevenod et al., 2000; Bentires-Alj et al., 2003) , and several groups have shown that curcumin downregulates MDR-1 expression in different cell types either through inhibiting the NF-kB pathway or by direct interaction (Anuchapreeda et al., 2002; Choi et al., 2008; Hou et al., 2008; Ganta and Amiji, 2009) . Our data suggest that the inhibition of MDR-1 expression by curcumin in 3-MC-induced tumor samples can enhance the intracellular accumulation of paclitaxel and contribute, at least in part, to the synergistic effect of these agents.
Constitutive and drug-induced activation of the serine threonine kinase Akt and the three major MAPKs-ERK1/2, p38 and JNK-have been widely implicated in cancer cell proliferation, survival and resistance to apoptotic stimuli (Chang and Karin, 2001; Cantley, 2002; Hokeness et al., 2005) . Paclitaxel has been reported to activate Akt (Mabuchi et al., 2002; Hokeness et al., 2005) and MAPK pathways (Liu et al., 2001; Kuo et al., 2006; Yagi et al., 2009 ) and thereby compromises its apoptotic potential, whereas inhibition of these pathways by curcumin increases susceptibility of cancer cells to chemotherapeutic agents (Bava et al., 2005; Aggarwal et al., 2006; Gagnon et al., 2008) . Although activated JNK contributes to some apoptotic responses, the JNK-dependent apoptotic signaling pathways can be blocked by activation of NF-kB and Akt pathways (Xia et al., 1995) . As curcumin remarkably inhibited the activation of MAPKs in 3-MC-induced tumors, it could attenuate the DNA-binding activity of the downstream transcription factor AP-1. Furthermore, activated Akt can contribute to the induction of NF-kB activity (Kane et al., 1999) . Nevertheless, downregulation of Akt activation, ERK1/2 and JNK pathways and DNAbinding activity of AP-1 by curcumin are possible mechanisms by which the 3-MC-induced tumors are sensitized to paclitaxel therapy. Our recently published data on the modulation of paclitaxel-induced MAPK signaling by curcumin in HeLa cells in vitro also substantiate these findings (Bava et al., 2010) .
Moreover, in vitro studies using the carcinoma cells isolated from 3-MC-induced tumors and xenograft studies using HeLa cells provide direct evidence that chemosensitization to paclitaxel-induced cytotoxicity by curcumin involves downregulation of paclitaxel-induced NF-kB and augmentation of the proapoptotic effects of paclitaxel, both in vitro and in vivo. Collectively, we have shown that curcumin, the pharmacologically safe chemosensitizer, can significantly augment the anticancer potential of paclitaxel by targeting multiple signaling events using well-defined preclinical models, and these in vivo evidences on the existence of therapeutic synergism between these agents underscore the essential need for validating this combination through clinical trials.
Materials and methods

Reagents and antibodies
Paclitaxel, rhodamine-conjugated anti-mouse IgG and fluorescein-conjugated anti-rabbit IgG were procured from Calbiochem (San Diego, CA, USA). Dulbecco's modied Eagle's medium was obtained from Life Technologies (Grand Island, NY, USA). Mouse monoclonal antibodies against p65, Bcl-2, MDR-1, MMP-2, MMP-9 and VEGF; rabbit polyclonals against p50, ERK-2, JNK-1, p38 and poly(ADPribose) polymerase; goat polyclonal anti-Cox-2 and the Annexin V apoptosis detection kit were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). The mouse monoclonals anti-cyclin D1 and anti-proliferating cell nuclear antigen, rabbit polyclonals against Akt, caspase-3, caspase-7, caspase-8, caspase-9, c-IAP1, phospho-Akt, phospho-p38, phospho-ERK-1/2, phospho-SAPK/JNK and rabbit monoclonal against survivin was obtained from Cell Signaling Technology (Beverly, MA, USA). Mouse monoclonal anti-XIAP was procured from BD Biosciences (San Diego, CA, USA). All other reagents and antibodies were obtained from SigmaAldrich Biochemicals (St Louis, MO, USA).
Animal experiments
All animal studies were done in accordance with the Institute animal ethics committee-approved protocols. Murphy's string method (Murphy, 1961; Hussain and Rao, 1991) was followed for tumor induction in the uterine cervices of 6-week-old virgin female Swiss albino mice. Carcinogen (B600 mg) impregnated cotton threads or similar cotton threads without carcinogen were inserted into the canal of uterine cervix of Swiss albino mice. Tumor development was checked by palpation thrice a week, starting from day 15 of tumor induction. After 30 days, the size of palpable tumors in the 3-MC-treated animals were measured using a vernier caliper and the animals were randomized into four groups (n ¼ 12), ensuring even distribution of tumor sizes in each group before drug administration. The control animals were also grouped into two (n ¼ 12) and drug administration was started the same day as indicated in Figure 1A . Curcumin was encapsulated into a unilamellar liposome formulation containing phosphatidyl choline and cholesterol (Kuttan et al., 1985) and injected intraperitoneally on alternate days at the dose of 25 mg/kg body weight. Paclitaxel was dissolved in Cremophor vehicle (Cremophor EL/ethanol 1:1, diluted 1:4 with phosphate-buffered saline) and injected intraperitoneally at 10 mg/kg doses twice weekly. The control animals were injected with empty liposomes and/ or Cremophor vehicle. The drug treatment was continued until the animals were killed on day 120 and the cervical tumors or the normal cervices were excised. Tumor volume was calculated as (length Â width 2 )/2. The xenograft studies to evaluate the efficacy of paclitaxel and curcumin, either alone or in combination against human cervical cancer cells in vivo, were carried out in female, 6-weekold nulliparous NOD-SCID mice. HeLa cells (5 Â 10 6 ) were injected subcutaneously in the flank of a NOD-SCID female mouse and after 4 weeks, when the xenograft tumor reached a volume of B2.5 cm3, the tumor was excised, cut into small pieces (B0.5 Â 0.5 mm) and these tumor fragments were subcutaneously transplanted into the left flank of 24 NOD-SCID mice using a 11-gauge trocar. Then, six animals each were randomly assigned to four study cohorts including a positive control group where the animals were left untreated, a paclitaxel-alone group, a curcumin-alone group and the combination group where the animals received both paclitaxel and curcumin. Drug administration was started when the tumors reached the volume of B50 mm 3 . The route and dose of drug administration were exactly the same as that followed in the carcinogen-induced cervical tumor model in Swiss albino mice and continued up to 6 weeks, after which the animals were killed and the tissue samples were collected for further analyses.
Preparation of nuclear extracts and EMSA Nuclear extracts from tissue samples or cultured cells were prepared and EMSA was performed to evaluate DNA-binding activity of NF-kB or AP-1 essentially as described elsewhere (Chaturvedi et al., 2000; Banerjee et al., 2002) .
Histology and immunohistochemistry
For histopatholgical examination, 5 mm sections cut from the formalin-fixed, paraffin-embedded tissues were deparaffinized, rehydrated, stained with hematoxylin and eosin and mounted with distyrene plasticizer and xylene (DPX) mountant. Immunolocalization of specific proteins in the tissue sections was done using the Iso-IHC kit (Biogenex Laboratories Inc., San Ramon, CA, USA) following the manufacturer's instructions. Photomicrographs were captured using a Nikon Eclipse E600 microscope (Nikon Instruments Inc., Melville, NY, USA).
RNA extraction and real-time quantitative PCR Total RNA was extracted from tissue samples using TRIZOL reagent (Invitrogen Corporation, Carlsbad, CA, USA). RNA (5 mg) was used for complementary DNA synthesis using Moloney murine leukemia virus reverse transcriptase and random hexamers (Promega Corporation, Madison, WI, USA). Real-time quantitative PCR analysis was performed on an ABI 7500 Real-Time PCR System (Applied Biosystems, Carlsbad, CA, USA) with 2ml of complementary DNA in a total reaction volume of 20 ml using the SYBR Green PCR mix (Eurogentec, Seraing, Belgium). The primers and reaction conditions are described in Supplementary Table S1 . Fold change in expression levels between normal and other treatment groups was calculated relative to the endogenous gene, b-actin, using the 2 ÀDDCt method (Livak and Schmittgen, 2001 ).
Western blot analysis
Tissue samples or cells were lysed in ice-cold RIPA buffer with protease inhibitors and western blotting was performed as described (Bava et al., 2005) .
Isolation of cells and primary culture
Primary epithelial cells were isolated from the tumor tissues and cultured according to established methods (Freshney and Freshney, 2002) . Immediately after excision, tumor tissue was minced and subjected to overnight collagenase digestion at 4 1C.
The tissue digest was washed with phosphate-buffered saline containing antibiotics and antimicotic and incubated with Dulbecco's modied Eagle's medium supplemented with 20% fetal bovine serum and antibiotics. Fibroblast contamination was removed by controlled trypsinization and low-passage cells (o6) were used for subsequent experiments. The normal cervical cells from mice were also isolated by similar procedure.
Cell viability assay
The in vitro cytotoxicity of the compounds was determined by MTT assay as described earlier (Bava et al., 2005) .
Flow cytometry and cell cycle analysis Cells exposed to the compounds as indicated for 24 h were fixed in 70% ice-cold ethanol, treated with 100mg/ml of RNase A and 50 mg/ml propidium iodide, and subjected to flow cytometry using a flow cytometer (BD Biosciences).
Annexin staining
To identify phosphatidylserine externalization, cells were stained with fluorescein isothiocyanate-conjugated Annexin V (Santa Cruz Biotechnology) according to the manufacturer's instructions followed by flow cytometry.
Immunocytochemistry
Cells grown on coverslips were treated with curcumin for 4 h followed by paclitaxel for 30 min, fixed with acetone/methanol (1:1), and immunostaining was done with mouse monoclonal anti-p65 or rabbit polyclonal anti-p50 antibodies followed by rhodamine-or fluorescein-conjugated secondary antibodies. Nuclei were stained with 4,6-diamidino-2-phenylindole and images were taken on a Nikon Eclipse E600 microscope equipped with Image-Pro Plus software (Media Cybernetics Inc., Silver Spring, MD, USA).
TUNEL assay
TUNEL assay was performed to detect apoptosis in formalinfixed, paraffin-embedded xenograft tumor tissue sections using DeadEnd Colorimetric TUNEL System (Promega) following the manufacturer's instructions.
Statistical analysis
Data are presented as mean±s.e. of three independent experiments. Two-tailed Student's t-test was used for statistical analysis. A P-value of o0.05 was considered statistically significant.
